Table 1.
Characteristics of Responders and Non-Responders
| Variable, N (%) | Responder | Non-Responder | Total | p-value | |||
|---|---|---|---|---|---|---|---|
| >50% Relief | <50% Relief | Total | |||||
| TOTALa | 10 (14%) | 35 (50%) | 45 (64%) | 25 (36%) | 70 | ||
| Pain Diagnosis | 0.0045b | ||||||
| Neuropathic pain/ neuropathy/radicular pain | 6 (29%) | 8 (38%) | 14 (67%) | 7 (33%) | 21 | ||
| CRPS | 2 (17%) | 7 (58%) | 9 (75%) | 3 (25%) | 12 | ||
| Fibromyalgia | 0 | 9 (90%) | 9 (90%) | 1 (10%) | 10 | ||
| FBSS | 1 (14%) | 4 (57%) | 5 (71%) | 2 (29%) | 7 | ||
| Spondylosis/axial LBP | 1 (6%) | 5 (28%) | 6 (33%) | 12 (67%) | 18 | ||
| Cancer Pain | 0 | 1 (100%) | 1 (100%) | 0 | 1 | ||
| Other | 0 | 1 (100%) | 1 (100%) | 0 | 1 | ||
| Sex | 1.0c | ||||||
| Male | 3 (27%) | 4 (36%) | 7 (64%) | 4 (36%) | 11 | ||
| Female | 7 (12%) | 31 (53%) | 38 (64%) | 21 (36%) | 59 | ||
| Length of Time | To First Response | To Stop | NA | ||||
| < 1 month | 7 (16%) | 7 (28%) | 14 | ||||
| 1–3 months | 31 (72%) | 13 (52%) | 44 | ||||
| 3–6 months | 5 (12%) | 3 (12%) | 8 | ||||
| 6–9 months | 0 | 2 (8%) | 2 | ||||
| Not Documented | 2 (NA) | 2 | |||||
| Side Effects | 6 (+3) | 6 | NA | ||||
| Vivid Dreams | 3 | ||||||
| Nightmares | 1 | ||||||
| Night Sweats | |||||||
| Allergy | |||||||
| Difficulty Sleeping | 1 (d/c’d) | ||||||
| Rash | 1 (d/c’d) | ||||||
| Nausea | 2 (d/c’d) | ||||||
| Headaches | 1 | ||||||
| Chest Heaviness | 1(d/c’d) | ||||||
| Face Twitching | 1 (d/c’d) | ||||||
| Other | 1 | ||||||
| Improved Sleep | 3 | ||||||
Notes: aN=70 patients total, of whom n=25 (36%) had no response and n=45 (64%) had a response. Of the n=45 who had a response, n=10 (14% of total) had ≥50% response while n=35 (50% of total) had <50% response. bChi-Square Test: Response 2 groups; Disease in 3: spondylosis, fibromyalgia, other. Excludes cancer/other. cFisher’s Exact Test, Responder vs Non-responder.
Abbreviations: FBSS, Failed Back Surgery Syndrome; LBP, Lower Back Pain; CRPS, Complex Regional Pain Syndrome. d/c’d, Discontinued LDN due to side effect.